Inherited Thrombophilias

Obstetrics and Gynecology Clinics of North America

Volumn 33, Issue 3, 2006, Pages 357-374

  Coppens, Michiel ^a   Kaandorp, Stef P ^a   Middeldorp, Saskia ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABORTION; CLINICAL PRACTICE; FEMALE; GENETIC DISORDER; HUMAN; PATHOPHYSIOLOGY; PATIENT COUNSELING; PREECLAMPSIA; PREGNANCY COMPLICATION; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; THROMBOPHILIA; VENOUS THROMBOEMBOLISM; WOMEN'S HEALTH;

ABORTION, HABITUAL; FEMALE; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MUTATION; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 33748466171     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ogc.2006.05.011     Document Type: Review

References (93)

1. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 13 (1965) 516-530
2. Rosendaal F.R. Risk factors for venous thrombotic disease. Thromb Haemost 82 (1999) 610-619
3. Rosendaal F.R. Venous thrombosis: a multicausal disease. Lancet 353 (1999) 1167-1173
4. Lin J., and August P. Genetic thrombophilias and preeclampsia: a meta-analysis. Obstet Gynecol 105 (2005) 182-192
5. Rey E., Kahn S.R., David M., et al. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 361 (2003) 901-908
6. Bauer K.A., and Rosenberg R.D. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood 70 (1987) 343-350
7. Boisclair M.D., Ireland H., and Lane D.A. Assessment of hypercoagulable states by measurement of activation fragments and peptides. Blood Rev 4 (1990) 25-40
8. Lane D.A., Bayston T., Olds R.J., et al. Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 77 (1997) 197-211
9. Reitsma P.H., Bernardi F., Doig R.G., et al. Protein C deficiency: a database of mutations, 1995 update. On behalf of the Subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 73 (1995) 876-889
10. Gandrille S., Borgel D., Sala N., et al. Protein S deficiency: a database of mutations-summary of the first update. Thromb Haemost 84 (2000) 918
11. Bertina R.M., Koeleman B.P., Koster T., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369 (1994) 64-67
12. Voorberg J., Roelse J., Koopman R., et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet 343 (1994) 1535-1536
13. Poort S.R., Rosendaal F.R., Reitsma P.H., et al. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88 (1996) 3698-3703
14. Koster T., Blann A.D., Briet E., et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345 (1995) 152-155
15. Bank I., Libourel E.J., Middeldorp S., et al. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost 3 (2005) 79-84
16. Kamphuisen P.W., Houwing-Duistermaat J.J., van Houwelingen H.C., et al. Familial clustering of factor VIII and von Willebrand factor levels. Thromb Haemost 79 (1998) 323-327
17. Kraaijenhagen R.A., in't Anker P.S., Koopman M.M., et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 83 (2000) 5-9
18. O'Donnell J., Mumford A.D., Manning R.A., et al. Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost 83 (2000) 10-13
19. den Heijer M., Rosendaal F.R., Blom H.J., et al. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost 80 (1998) 874-877
20. Jacques P.F., Bostom A.G., Williams R.R., et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. [see comments]. Circulation 93 (1996) 7-9
21. Brattstrom L., Wilcken D.E., Ohrvik J., et al. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 98 (1998) 2520-2526
22. Heijboer H., Brandjes D.P., Buller H.R., et al. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 323 (1990) 1512-1516
23. Middeldorp S., Henkens C.M., Koopman M.M., et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med 128 (1998) 15-20
24. Simioni P., Sanson B.J., Prandoni P., et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 81 (1999) 198-202
25. Bank I., Libourel E.J., Middeldorp S., et al. Prothrombin 20210A mutation: a mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study. Arch Intern Med 164 (2004) 1932-1937
26. Tait R.C., Walker I.D., Davidson J.F., et al. Antithrombin III activity in healthy blood donors: age and sex related changes and prevalence of asymptomatic deficiency. [letter; comment]. Br J Haematol 75 (1990) 141-142
27. Tait R.C., Walker I.D., Reitsma P.H., et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemost 73 (1995) 87-93
28. Lindqvist P.G., Svensson P.J., Marsaal K., et al. Activated protein C resistance (FV:Q506) and pregnancy. Thromb Haemost 81 (1999) 532-537
29. Vandenbroucke J.P., Koster T., Briet E., et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 344 (1994) 1453-1457
30. van Dongen C.J., Vink R., Hutten B.A., et al. The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-analysis. Arch Intern Med 163 (2003) 1285-1293
31. Weitz J.I., Middeldorp S., Geerts W., et al. Thrombophilia and new anticoagulant drugs. Hematology (Am Soc Hematol Educ Program) 1 (2004) 424-438
32. Kearon C. Long-term management of patients after venous thromboembolism. Circulation 110 (2004) I10-I18
33. Sanson B.J., Friederich P.W., Simioni P., et al. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost 75 (1996) 387-388
34. Preston F.E., Rosendaal F.R., Walker I.D., et al. Increased fetal loss in women with heritable thrombophilia. Lancet 348 (1996) 913-916
35. Meinardi J.R., Middeldorp S., de Kam P.J., et al. Increased risk for fetal loss in carriers of the factor V Leiden mutation. Ann Intern Med 130 (1999) 736-739
36. Regan L., and Rai R. Epidemiology and the medical causes of miscarriage. Baillieres Best Pract Res Clin Obstet Gynaecol 14 (2000) 839-854
37. Krabbendam I., Franx A., Bots M.L., et al. Thrombophilias and recurrent pregnancy loss: a critical appraisal of the literature. Eur J Obstet Gynecol Reprod Biol 118 (2005) 143-153
38. Farquharson R.G., Jauniaux E., and Exalto N. Updated and revised nomenclature for description of early pregnancy events. Hum Reprod 20 (2005) 3008-3011
39. Alfirevic Z., Roberts D., and Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur J Obstet Gynecol Reprod Biol 101 (2002) 6-14
40. Dudding T.E., and Attia J. The association between adverse pregnancy outcomes and maternal factor V Leiden genotype: a meta-analysis. Thromb Haemost 91 (2004) 700-711
41. Kovalevsky G., Gracia C.R., Berlin J.A., et al. Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss: a meta-analysis. Arch Intern Med 164 (2004) 558-563
42. Marietta M., Facchinetti F., Sgarbi L., et al. Elevated plasma levels of factor VIII in women with early recurrent miscarriage. J Thromb Haemost 1 (2003) 2536-2539
43. Middeldorp S., Van de Poel M.H., Bank I., et al. Unselected women with elevated levels of factor VIII:C or homocysteine are not at increased risk for obstetric complications. Thromb Haemost 92 (2004) 787-790
44. Nelen W.L., Blom H.J., Steegers E.A., et al. Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis. Fertil Steril 74 (2000) 1196-1199
45. Morrison E.R., Miedzybrodzka Z.H., Campbell D.M., et al. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost 87 (2002) 779-785
46. Witsenburg C.P., Rosendaal F.R., Middeldorp J.M., et al. Factor VIII levels and the risk of pre-eclampsia, HELLP syndrome, pregnancy related hypertension and severe intrauterine growth retardation. Thromb Res 115 (2005) 387-392
47. Middeldorp S., Henkens C.M.A., Koopman M.M.W., et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med 128 (1998) 15-20
48. Middeldorp S., Buller H.R., Prins M.H., et al. Approach to the thrombophilic patient. In: Colman R.W., Hirsh J., Marder V.J., et al. (Eds). Hemostasis and thrombosis: basic principles and clinical practice. 4th edition (2001), Lippincott Williams & Wilkins, Philadelphia 1085-1100
49. Hutten B.A., and Prins M.H. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Database (2000) CD001367
50. Baglin C., Brown K., Luddington R., et al. Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FVR506Q) mutation: effect of warfarin and prediction by precipitating factors. East Anglian Thrombophilia Study Group. Br J Haematol 100 (1998) 764-768
51. van der Meer F.J., Rosendaal F.R., Vandenbroucke J.P., et al. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 153 (1993) 1557-1562
52. Palareti G., Leali N., Coccheri S., et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 348 (1996) 423-428
53. Bergqvist D., Benoni G., Bjorgell O., et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 335 (1996) 696-700
54. Planes A., Vochelle N., Darmon J.Y., et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 348 (1996) 224-228
55. Bates S., Greer I.A., Hirsh J., et al. Use of antithrombotic agents during pregnancy. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 (2004) 627S-44S
56. Vandenbroucke J.P., Rosing J., Bloemenkamp K.W., et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 344 (2001) 1527-1535
57. Jick H., Kaye J.A., Vasilakis-Scaramozza C., et al. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ 321 (2000) 1190-1195
58. Spitzer W.O., Lewis M.A., Heinemann L.A., et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 312 (1996) 83-88
59. Buller H.R., Agnelli G., Hull R.D., et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 401S-28S
60. Christiansen S.C., Cannegieter S.C., Koster T., et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 293 (2005) 2352-2361
61. Brill-Edwards P., Ginsberg J.S., Gent M., et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. N Engl J Med 343 (2000) 1439-1444
62. Pabinger I., Grafenhofer H., Kaider A., et al. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost 3 (2005) 949-954
63. Van Driel D., Wesseling J., Sauer P.J., et al. In utero exposure to coumarins and cognition at 8 to 14 years old. Pediatrics 107 (2001) 123-129
64. Wesseling J., Van Driel D., Heymans H.S., et al. Behavioural outcome of school-age children after prenatal exposure to coumarins. Early Hum Dev 58 (2000) 213-224
65. Wesseling J., Van Driel D., Smrkovsky M., et al. Neurological outcome in school-age children after in utero exposure to coumarins. Early Hum Dev 63 (2001) 83-95
66. Sanson B.J., Lensing A.W., Prins M.H., et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 81 (1999) 668-672
67. Tengborn L., Bergqvist D., Matzsch T., et al. Recurrent thromboembolism in pregnancy and puerperium. Is there a need for thromboprophylaxis?. Am J Obstet Gynecol 160 (1989) 90-94
68. den Heijer M., Willems H., Blom H.J., et al. Homocysteine lowering by B vitamins and the secondary prevention of deep-vein thrombosis and pulmonary embolism. A randomised, placebo-controlled, double blind trial. J Thromb Haemost 3 (2005) H03
69. Hoibraaten E., Qvigstad E., Arnesen H., et al. Increased risk of recurrent venous thromboembolism during hormone replacement therapy. Results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 84 (2000) 961-967
70. Rai R., Cohen H., Dave M., et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 314 (1997) 253-257
71. Empson M, Lassere M, Craig JC, et al. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. The Cochrane Database of Systematic Reviews. 2005;CD002859.
72. Gris J.C., Neveu S., Tailland M.L., et al. Use of a low-molecular weight heparin (enoxaparin) or of a phenformin-like substance (moroxydine chloride) in primary early recurrent aborters with an impaired fibrinolytic capacity. Thromb Haemost 73 (1995) 362-367
73. Brenner B., Hoffman R., Blumenfeld Z., et al. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost 83 (2000) 693-697
74. Younis J.S., Ohel G., Brenner B., et al. The effect of thromboprophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation. Br J Obstet Gynaecol 107 (2000) 415-419
75. DiNisio M, Peters LW, Middeldorp S. Anticoagulants for the treatment of recurrent pregnancy loss in women without antiphospholipid syndrome. The Cochrane Database of Systematic Reviews 2005;CD004734.
76. Gris J.C., Mercier E., Quere I., et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 103 (2004) 3695-3699
77. Brenner B., Hoffman R., Carp H., et al. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. J Thromb Haemost 3 (2005) 227-229
78. Middeldorp S. The use of LMWH in pregnancies at risk: new evidence or perception?. J Thromb Haemost 3 (2005) 788-789
79. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet 343 (1994) 619-629
80. Duley L, Henderson-Smart DJ, Knight M, et al. Antiplatelet agents for preventing and its complications pre-eclampsia (Cochrane Review). The Cochrane Library; 2003;CD004659.
81. Miletich J., Sherman L., and Broze Jr. G. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 317 (1987) 991-996
82. Tait R.C., Walker I.D., Perry D.J., et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 87 (1994) 106-112
83. Rees D.C., Cox M., and Clegg J.B. World distribution of factor V Leiden. Lancet 346 (1995) 1133-1134
84. Ridker P.M., Miletich J.P., Hennekens C.H., et al. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 277 (1997) 1305-1307
85. Dilley A., Austin H., Hooper W.C., et al. Prevalence of the prothrombin 20210 G-to-A variant in blacks: infants, patients with venous thrombosis, patients with myocardial infarction, and control subjects. J Lab Clin Med 132 (1998) 452-455
86. Rosendaal F.R., Doggen C.J., Zivelin A., et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 79 (1998) 706-708
87. Cumming A.M., Keeney S., Salden A., et al. The prothrombin gene G20210A variant: prevalence in a UK anticoagulant clinic population. Br J Haematol 98 (1997) 353-355
88. den Heijer M., Koster T., Blom H.J., et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 334 (1996) 759-762
89. Sanson B.J., Simioni P., Tormene D., et al. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study. Blood 94 (1999) 3702-3706
90. Middeldorp S., Meinardi J.R., Koopman M.M., et al. A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med 135 (2001) 322-327
91. Coppens M., Van de Poel M.H., Hamulyak K., et al. Incidence of venous and arterial thromboembolism in asymptomatic carriers of the prothrombin 20210A mutation-a prospective cohort study. J Thromb Haemost 3 Suppl 1 (2005) P0459
92. Bank I., Coppens M., Van de Poel M.H., et al. A prospective cohort study of asymptomatic individuals with elevated factor VIII:c to determine the absolute incidence of venous and arterial thromboembolism. J Thromb Haemost 3 Suppl 1 (2005) 1056
93. Van de Poel M.H., Coppens M., Middeldorp S., et al. Absolute risk of venous and arterial thromboembolism associated with mild hyperhomocysteinemia. Results from a retrospective family cohort study. J Thromb Haemost 3 Suppl 1 (2005) P0481